Abstract: The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.

Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

Abstract: A system for housing a supply of aquatic organisms includes a plurality of holding tanks and a subsystem for continuously delivering fluid to each holding tank to ensure a suitable living environment. The subsystem includes a conduit in communication with each holding tank, a pump for driving the fluid through the conduit, a filter for removing impurities in the fluid driven by the pump, and a pressure sensor for measuring the pressure level of fluid traveling within the conduit. A water treatment controller in communication with the pressure sensor monitors the pressure level of fluid in the conduit and compensates for pressure level variances by adjusting the operating speed of the pump to ensure that fluid is delivered to the tanks at a constant flow rate. In this manner, the fluid delivery flow rate remains constant even as particulate blockages begin to form on the filter.

Abstract: Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.

Abstract: The technology disclosed provides systems and methods that display database objects representing entities, placement channels and workflow status in an insurance or other risk transfer program. Specially coded distribution trees and graphs of nodes represent the overall flow and, optionally, status of placement workflows. Node and edge data generated for display depicts multiple risk placements on behalf of at least one requesting party through intermediaries to responding parties. Line width of edges represents calculated relative size of placements, and pattern, style, and color of edges can depict statuses of the risk placements. Another geo-coded map display also depicts as nodes a requesting party, intermediaries and responding parties, connected by edges that represent communication channels.

Abstract: Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.

Abstract: A high frequency data recorder (“HFDR”) can include a first set of contacts, on a first side of the HFDR, that are pluggable into a first meter receptacle of a meter box, wherein the first meter receptacle provides a connection to a power supply and a connection to a load. The HFDR also includes a second set of contacts, on a second side of the HFDR, that form a second meter receptacle. The second meter receptacle provides another connection to the power supply and another connection to the load. The HFDR can further include a processor that accesses a non-transitory machine readable memory that stores instruction that when executed cause the processor to passively measures current downstream from the meter box. The HFDR still further includes a wireless transceiver that wirelessly transmits data characterizing the measured current.

Abstract: The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.

Abstract: The technology disclosed provides systems and methods that display database objects representing entities, placement channels and workflow status in an insurance or other risk transfer program. Specially coded distribution trees and graphs of nodes represent the overall flow and, optionally, status of placement workflows. Node and edge data generated for display depicts multiple risk placements on behalf of at least one requesting party through intermediaries to responding parties. Line width of edges represents calculated relative size of placements, and pattern, style, and color of edges can depict statuses of the risk placements. Another geo-coded map display also depicts as nodes a requesting party, intermediaries and responding parties, connected by edges that represent communication channels.

Abstract: An automated system for administering food to laboratory animals housed in aquatic tanks includes a plurality of individual feeding units that independently communicate with a common feed management hub. Each feeding unit includes a rack for holding a collection of aquatic tanks and a wireless robotic feeder configured to move in three dimensions relative to the rack. The robotic feeder precisely meters and delivers liquid and/or dry food to each rack-mounted tank in accordance with user-modifiable feed schedules which are maintained by the feed management hub. To compensate for any adjustments to the particular arrangement of tanks within a feeding unit, the robotic feeder periodically scans the rack for tanks and transmits the scan data back to the feed management hub. Accordingly, the feed management hub ensures that the proper type of food is accurately and timely delivered to each aquatic tank in compliance with the stored feed schedules.

Abstract: Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes of the various embodiments of the present invention.

Abstract: A method may include defining, based on one or more user inputs, a custom type including one or more fields having one or more capabilities. In response to a first request from a publish service, the custom type may be sent to the publish service such that the publish service publishes, to a search system, one or more documents in accordance with a schema specified by the custom type. In response to a second request from a search service, a response may be sent to the search service identifying one or more field names and/or methods at the search system that correspond to one or more fields and/or actions specified by a first query received at the search service. The one or more field names and/or methods may be identified based at least on the custom type. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: A method may include defining, based on one or more user inputs, a custom type including one or more fields having one or more capabilities. In response to a first request from a publish service, the custom type may be sent to the publish service such that the publish service publishes, to a search system, one or more documents in accordance with a schema specified by the custom type. In response to a second request from a search service, a response may be sent to the search service identifying one or more field names and/or methods at the search system that correspond to one or more fields and/or actions specified by a first query received at the search service. The one or more field names and/or methods may be identified based at least on the custom type. Related systems and articles of manufacture, including computer program products, are also provided.

Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

Abstract: A high frequency data recorder (“HFDR”) can include a first set of contacts, on a first side of the HFDR, that are pluggable into a first meter receptacle of a meter box, wherein the first meter receptacle provides a connection to a power supply and a connection to a load. The HFDR also includes a second set of contacts, on a second side of the HFDR, that form a second meter receptacle. The second meter receptacle provides another connection to the power supply and another connection to the load. The HFDR can further include a processor that accesses a non-transitory machine readable memory that stores instruction that when executed cause the processor to passively measures current downstream from the meter box. The HFDR still further includes a wireless transceiver that wirelessly transmits data characterizing the measured current.

Abstract: Embodiments of the invention provide a tank assembly with a main housing enclosing an inner volume, and an outlet section positioned extending from one end of the main housing that includes a front cavity with an outlet volume and an adjacent outlet channel. Some embodiments include at least one removable filter configured to be inserted at least partially into main housing forming at least a filtered volume and a fluidly coupled main volume. Some embodiments include a removable tank baffle including at least one central channel and a plurality of baffle apertures. In some embodiments, the central channel is configured to be fluidly coupled to the outlet channel when the removable tank baffle is positioned in the main housing. Further, the plurality of baffle apertures are configured to be fluidly coupled to the outlet volume when the removable tank baffle is positioned in the main housing.

Abstract: Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.

Abstract: Clinical diagnosis and newborn screening for primary immunodeficiencies (PIDDs) is described. The PIDDs include X-linked chronic granulomatous disease (X-CGD), X-linked lymphoproliferative syndrome (XLP1; SH2D1A deficiency), familial hemophagocytic lymphohistiocytosis 2 (FHL2), ataxia telangiectasia (AT), common variable immunodeficiency (CVID; B-cell dysfunctions), severe combined immunodeficiency (SCID), adenosine deaminase (ADA) deficiency, and dedicator of cytokinesis 8 (DOCKS) deficiency. Additionally, cell specific markers for platelets (CD42), natural killer (NK) cells (CD56), and T cells (CD3epsilon and CD3delta) can be used as secondary markers to provide support for diagnosis of disease.

Abstract: Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes of the various embodiments of the present invention.